Clinical Observation of Raltitrexed-based Regimen for Advanced Primary Liver Carcinoma

Objective To evaluate clinical efficacy and adverse events of raltitrexed-based regimens for advanced primary liver carcinoma patients.

Methods A total of 31 advanced primary liver carcinoma patients were treated with raltitrexed-based regimens, 14 patients were the second-line treatment, 10 patients were the third-line treatment and 7 patients were the fourth-line treatment. The chemotherapy regimens were irinotecan (CPT-11), oxaliplatin (AXO), gemcitabine (GEM) combined with raltitrexed respectively and single raltitrexed. The efficacy of all patients were evaluated according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The adverse events were evaluated by Common Terminology Criteria for Adverse Events Version 4.0 (NCN-CTC 4.0).

Results Thirty-one patients could be evaluated. No one achieved complete response (CR) or partial response (PR), 13 patients achieved stable disease (SD) and 18 patients achieved progressive disease (PD). The effective rate (CR+PR) was 0%. The disease control rate (CR+PR+SD) was 41.9%. The median time to progression (mTTP) and median overall survival (mOS) were 63 and 189 days, respectively. The main adverse events were myelosuppression and gastrointestinal reactions. These adverse events wereⅠ~Ⅱ degree and well-tolerated.

Conclusion Raltitrexed-based regimens for advanced primary liver carcinoma are effective and well-tolerable. It may lengthen the overall survival and is worthy of further study.